Literature DB >> 23746122

Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome.

Huseyin Begenik1, Yasemin Usul Soyoral, Reha Erkoc, Habib Emre, Abdullah Taskın, Mehmet Tasdemir, Mehmet Aslan.   

Abstract

OBJECTIVES: Some studies have indicated the pathophysiological importance of reactive oxygen species (ROS) in patients with nephrotic syndrome. Myeloperoxidase (MPO) is a leukocyte-derived enzyme-generating ROS that has been proposed to exert a wide array of pro-atherogenic effects throughout all stages of the atherosclerotic process. The aim of this study was to investigate the serum malondialdehyde (MDA) levels, MPO and catalase activities in patients with adult nephrotic syndrome. PATIENTS AND
METHOD: s Twenty-four patients with nephrotic syndrome and 24 healthy controls were enrolled. Serum MPO activity, catalase activity, and MDA levels were assessed.
RESULTS: Serum MPO activity and MDA levels were significantly higher in patients with nephrotic syndrome than controls (both, P<0.001), while catalase activity was significantly lower (P<0.001). Serum catalase activity was found to be significantly correlated with MPO activity (r=-0.417, P=0.003) and MDA levels (r=-0.532, P=0.007). The serum MDA levels were also found to be significantly correlated with MPO activity (r=0.419, P=0.003).
CONCLUSIONS: We concluded that serum MPO activity and oxidative stress were increased and that serum catalase activity was decreased in patients with adult nephrotic syndrome. In addition, these results indicate that increased MPO activity is associated with an oxidant-antioxidant imbalance that may contribute to atherosclerosis in patients with adult nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23746122      PMCID: PMC6837727          DOI: 10.1179/1351000213Y.0000000048

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  40 in total

1.  Oxidative stress status in adults with nephrotic syndrome.

Authors:  F Bulucu; A Vural; A Aydin; A Sayal
Journal:  Clin Nephrol       Date:  2000-03       Impact factor: 0.975

Review 2.  Lipid-induced glomerular injury.

Authors:  C Guijarro; W F Keane
Journal:  Nephron       Date:  1994       Impact factor: 2.847

Review 3.  A classification of unstable angina revisited.

Authors:  C W Hamm; E Braunwald
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

Review 4.  Myeloperoxidase.

Authors:  C C Winterbourn; M C Vissers; A J Kettle
Journal:  Curr Opin Hematol       Date:  2000-01       Impact factor: 3.284

5.  Glutathione peroxidase activity in patients with renal disorders.

Authors:  Mohamed A El-Far; Mohamed A Bakr; Sami E Farahat; Elsaid A Abd El-Fattah
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

Review 6.  Mechanisms of proteinuria in noninflammatory glomerular diseases.

Authors:  V J Savin
Journal:  Am J Kidney Dis       Date:  1993-04       Impact factor: 8.860

Review 7.  Role of iron and oxygen radicals in the progression of chronic renal failure.

Authors:  A C Alfrey
Journal:  Am J Kidney Dis       Date:  1994-02       Impact factor: 8.860

8.  Myeloperoxidase, a leukocyte-derived vascular NO oxidase.

Authors:  Jason P Eiserich; Stephan Baldus; Marie-Luise Brennan; Wenxin Ma; Chunxiang Zhang; Albert Tousson; Laura Castro; Aldons J Lusis; William M Nauseef; C Roger White; Bruce A Freeman
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

9.  Decreased antioxidant activity in hypercholesterolemic children with nephrotic syndrome.

Authors:  Jacek Zachwieja; Waldemar Bobkowski; Agnieszka Dobrowolska-Zachwieja; Marcin Zaniew; Janusz Maciejewski
Journal:  Med Sci Monit       Date:  2003-06

10.  Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.

Authors:  Marijn C Meuwese; Erik S G Stroes; Stanley L Hazen; Joram N van Miert; Jan Albert Kuivenhoven; Robert G Schaub; Nicholas J Wareham; Robert Luben; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  J Am Coll Cardiol       Date:  2007-06-21       Impact factor: 24.094

View more
  8 in total

1.  NOX-mediated impairment of PDGF-induced DNA synthesis in peripheral blood lymphocytes of children with idiopathic nephrotic syndrome.

Authors:  Amal Al-Eisa; Gursev S Dhaunsi
Journal:  Pediatr Res       Date:  2017-06-14       Impact factor: 3.756

2.  Naloxone pretreatment prevents kidney injury after liver ischemia reperfusion injury.

Authors:  Mohammad Ashrafzadeh Takhtfooladi; Mehran Shahzamani; Ahmad Asghari; Aris Fakouri
Journal:  Int Urol Nephrol       Date:  2016-04-07       Impact factor: 2.370

3.  Combined Catalase and ADH Inhibition Ameliorates Ethanol-Induced Myocardial Dysfunction Despite Causing Oxidative Stress in Conscious Female Rats.

Authors:  Fanrong Yao; Abdel A Abdel-Rahman
Journal:  Alcohol Clin Exp Res       Date:  2017-07-25       Impact factor: 3.455

4.  Emerging Role of Myeloperoxidase in the Prognosis of Nephrotic Syndrome Patients Before and After Steroid Therapy.

Authors:  Sreelatha Souparnika; Benedicta D'Souza; Vivian D'Souza; Sushanth Kumar; Poornima Manjrekar; Manohar Bairy; Rajeevalochana Parthasarathy; Srinivas Kosuru
Journal:  J Clin Diagn Res       Date:  2015-07-01

5.  Relationship between serum DHEAS and oxidative stress levels of body mass index in healthy postmenopausal women.

Authors:  Burhan Goy; Murat Atmaca; Mehmet Aslan; Rıfkı Ucler; Murat Alay; Ismet Seven; Halit Demir; Mustafa Ozturk
Journal:  Redox Rep       Date:  2016-02-23       Impact factor: 4.412

6.  Increased ischemia-modified albumin levels in children with steroid-sensitive nephrotic syndrome.

Authors:  Gokhan Cakirca; Ahmet Guzelcicek; Kenan Yilmaz; Cemal Nas
Journal:  Pak J Med Sci       Date:  2020 Nov-Dec       Impact factor: 1.088

7.  Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure.

Authors:  Matti Adam; Sven Meyer; Henning Knors; Anna Klinke; Ulf K Radunski; Tanja K Rudolph; Volker Rudolph; Joshua M Spin; Philip S Tsao; Angelika Costard-Jäckle; Stephan Baldus
Journal:  Sci Rep       Date:  2015-04-13       Impact factor: 4.379

8.  Tetrandrine may treat membranous glomerulopathy via P13K/Akt signaling pathway regulation: therapeutic mechanism validation using Heymann nephritis rat model.

Authors:  Jiazhen Yin; Jiazhen Lin; Jin Yu; Xia Wei; Bin Zhu; Caifeng Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.